stockrowBiohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Return on assets
Biohaven Ltd.'s return on assets over the twelve months to 30 September 2026 was −161.3%, down 22.8 percentage points from fiscal 2025 (−138.5%). Over the past ten years it has ranged from −440.5% (fiscal 2016) to −23.0% (fiscal 2020); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −138.5% | 11.49 |
| FY2024 | −150.0% | (80.55) |
| FY2023 | −69.5% | 72.41 |
| FY2022 | −141.9% | (90.31) |
| FY2021 | −51.6% | (28.57) |
| FY2020 | −23.0% | 143.73 |
| FY2019 | −166.7% | (56.45) |
| FY2018 | −110.3% | 49.79 |
| FY2017 | −160.1% | 280.45 |
| FY2016 | −440.5% | (370.92) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| ADMA ADMA Biologics Inc compare | 28.0% |
| VCEL Vericel Corporation compare | 6.86% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| IMNM Immunome, Inc. compare | −59.0% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| BHVN Biohaven Ltd. | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)